New antibody drug aims to regrow hair – first human trial underway

NCT ID NCT07317544

Recruiting now Disease control Sponsor: Absci Pty Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests whether ABS-201, an antibody that blocks a hormone receptor, is safe for treating hair loss. It starts with healthy volunteers and then includes people with male or female pattern baldness. Participants receive either the drug or a placebo and are monitored for about a year.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ABS-201 (a monoclonal antibody targeting the prolactin receptor)
What this could lead to: If safe and effective, ABS-201 could offer a new treatment option for hair loss by targeting a different biological pathway than current therapies.
What could go wrong: This is an early-phase trial focused on safety, not effectiveness. The drug may cause side effects or fail to improve hair growth. Results may not apply to all types of hair loss.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANDROGENETIC ALOPECIA (AGA) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

alopecia androgenetic alopecia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANDROGENETIC ALOPECIA (AGA) HEALTHY VOLUNTEERS - MALE AND FEMALE

Contacts and locations

Locations

Momentum Darlinghurst
RECRUITING

Sydney, New South Wales, 2010, Australia
Nucleus Network
RECRUITING

Melbourne, Victoria, 3004, Australia
Nucleus Network Brisbane
RECRUITING

Brisbane, Queensland, 4006, Australia
Sinclair Dermatology
RECRUITING

Melbourne, Victoria, 3002, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.